Considering EAAC1-mediated cysteine uptake as the rate-limiting step for neuronal GSH synthesis, a compound facilitating EAAC1 function might be a potential strategy for the treatment of GSH-related neurodegenerative diseases. This evidence concerns the gene SLC1A1 and neurodegenerative disease.